menu
    • menu
    [{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Platelet Lysate","moa":"Growth factor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Bone Marrow Concentrate","moa":"Progenitor cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Bone Marrow Stem Cell","moa":"Progenitor cell","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Platelet Poor Plasma","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Platelet Poor Plasma","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Stem Cell Support Formula","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Regenexx

    Menu

    Regenexx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BRTX-100

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Biorestorative Therapies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectu...

                            Details : BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 05, 2022

                            Lead Product(s) : BRTX-100

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Biorestorative Therapies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Platelet Rich Plasma

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial for Treating Painful Degenerative Disc Disease

                            Details : Platelet Rich Plasma is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Intervertebral Disc Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 18, 2022

                            Lead Product(s) : Platelet Rich Plasma

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stem Cell Support Formula

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Randomized Trial of Regenexx Stem Cell Support Formula

                            Details : Stem Cell Support Formula is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : Stem Cell Support Formula

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Platelet Lysate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nebulized PL for Post-COVID-19 Syndrome

                            Details : Platelet Lysate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 27, 2020

                            Lead Product(s) : Platelet Lysate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Platelet Poor Plasma

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

                            Details : Platelet Poor Plasma is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 07, 2018

                            Lead Product(s) : Platelet Poor Plasma

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bone Marrow Concentrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries

                            Details : Bone Marrow Concentrate is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Trauma, Nervous System.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 07, 2018

                            Lead Product(s) : Bone Marrow Concentrate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Platelet Poor Plasma

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage

                            Details : Platelet Poor Plasma is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 19, 2017

                            Lead Product(s) : Platelet Poor Plasma

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Regenexx

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bone Marrow Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD T...

                            Details : Bone Marrow Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 28, 2016

                            Lead Product(s) : Bone Marrow Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth